undamentalytics Newsletter
Sign in

Neuropace Inc revenue

Neuropace Inc's revenue was $100.0m in fiscal 2025, up 25.1% on the year before. Since fiscal 2020 ($41.1m) it has grown at a compound 19.4% a year. Over the last twelve months it was $98.8m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue414546658010099
Growth on the year before—+9.8%+0.7%+43.7%+22.1%+25.1%—
Gross profit30333248597779
Gross margin73.6%74.0%71.4%73.6%73.9%77.2%79.6%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Neuropace Inc $98.8m 16.9% 21.6%
Ceribell, Inc. $102m 31.7% —
Delcath Systems, Inc. $95.4m 35.8% 230.8%
Iradimed Corp $89.3m 11.0% 12.4%
Xtant Medical Holdings, Inc. $110m -14.3% 17.3%
Sanara Medtech Inc. $110m 13.0% 22.6%

Compare with peers

Head to head: CBLL vs NPCEDCTH vs NPCEIRMD vs NPCE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neuropace Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuropace Inc.